Benserazide, a well-tolerated prodrug used in combination with Levodopa to treat Parkinson’s disease, was identified in a screen for small molecules capable of binding to the Nedd4 family members WWP1 and WWP2 and interfering with the binding of PY-containing peptides. Here, NEDD4 is linked to Parkinson disease.